Editas Medicine, Inc.
EDIT
$2.90
-$0.03-1.02%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -88.56% | 228.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -88.56% | 228.00% | |||
| Cost of Revenue | -35.78% | 38.58% | |||
| Gross Profit | -454.60% | 78.23% | |||
| SG&A Expenses | -9.86% | -7.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.18% | 20.77% | |||
| Operating Income | -78.39% | 42.90% | |||
| Income Before Tax | -344.52% | 77.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -344.52% | 77.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -344.52% | 77.62% | |||
| EBIT | -78.39% | 42.90% | |||
| EBITDA | -85.60% | 44.55% | |||
| EPS Basic | -341.52% | 79.27% | |||
| Normalized Basic EPS | -156.02% | 64.24% | |||
| EPS Diluted | -341.52% | 79.27% | |||
| Normalized Diluted EPS | -156.02% | 64.24% | |||
| Average Basic Shares Outstanding | 0.64% | 7.95% | |||
| Average Diluted Shares Outstanding | 0.64% | 7.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||